BidaskClub downgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a sell rating in a report released on Thursday, January 23rd, BidAskClub reports.

A number of other brokerages also recently weighed in on CRSP. William Blair raised Crispr Therapeutics from a market perform rating to an outperform rating in a research note on Tuesday, November 19th. Piper Jaffray Companies reissued a buy rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research note on Monday, December 16th. Chardan Capital reissued a buy rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an outperform rating in a research report on Monday, November 25th. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $84.00 price target on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. Crispr Therapeutics presently has an average rating of Buy and a consensus price target of $75.95.

Shares of CRSP stock opened at $52.32 on Thursday. The stock’s 50 day simple moving average is $59.31 and its 200 day simple moving average is $52.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a twelve month low of $29.92 and a twelve month high of $74.00. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -113.74 and a beta of 3.25.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,618 shares of company stock worth $3,230,760. Company insiders own 21.40% of the company’s stock.

Several large investors have recently made changes to their positions in CRSP. NEXT Financial Group Inc boosted its stake in Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 549 shares in the last quarter. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics in the 3rd quarter valued at $26,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in Crispr Therapeutics in the 4th quarter valued at $26,000. Webster Bank N. A. acquired a new stake in Crispr Therapeutics in the 4th quarter valued at $26,000. Finally, US Bancorp DE boosted its stake in Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares in the last quarter. 50.01% of the stock is currently owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: What is quantitative easing?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link